NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation ...
Revelation Biosciences (REVB) announced dosing of the first patient in the PRIME, or PReconditioning IMmunostimulatory Evaluation, Phase 1b ...
State-owned construction firm PTPP announced Thursday that its Kalibaru Terminal Phase 1B project in Tanjung Priok Port had ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
ProMIS Neurosciences (PMN) announced important progress in the PRECISE-AD Phase 1b clinical trial with the dosing of multiple patients with its ...
Thursday announced it has begun a contract transition for the West Valley Demonstration Project (WVDP) Phase 1B Deactivation ...
Arcutis Biotherapeutics is advancing in alopecia areata and atopic dermatitis with ZORYVE. Learn why ARQT stock offers growth ...
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported ...
Public School Board is expected to decide where students will attend elementary school beginning in the 2025-26 academic year when Washington Elementary School will be closed. The school board ...
Jasper expects to report data around mid-year 2025 from 4 cohorts: the 240mg single dose cohort (4 additional patients), ...
Arcus Biosciences, Inc.’s RCUS share price has surged by 10.22%, which has investors questioning if this is right time to sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback